Merck & Co., Inc. $MRK Shares Purchased by Stratos Investment Management LLC

Stratos Investment Management LLC boosted its position in Merck & Co., Inc. (NYSE:MRK) by 5.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 135,281 shares of the company’s stock after acquiring an additional 6,952 shares during the period. Stratos Investment Management LLC’s holdings in Merck & Co., Inc. were worth $14,240,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. DLD Asset Management LP boosted its holdings in shares of Merck & Co., Inc. by 30.1% during the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock worth $3,986,675,000 after purchasing an additional 11,000,000 shares during the last quarter. Assenagon Asset Management S.A. grew its position in shares of Merck & Co., Inc. by 192.7% in the third quarter. Assenagon Asset Management S.A. now owns 5,496,664 shares of the company’s stock valued at $461,335,000 after purchasing an additional 3,618,532 shares during the period. Amundi lifted its position in Merck & Co., Inc. by 26.4% during the second quarter. Amundi now owns 16,532,657 shares of the company’s stock worth $1,363,480,000 after buying an additional 3,454,941 shares during the period. Invesco Ltd. boosted its holdings in Merck & Co., Inc. by 16.6% in the third quarter. Invesco Ltd. now owns 19,844,936 shares of the company’s stock valued at $1,665,585,000 after acquiring an additional 2,821,766 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its stake in shares of Merck & Co., Inc. by 20.7% during the third quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company’s stock valued at $1,336,877,000 after purchasing an additional 2,735,459 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $120.62 on Friday. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. The firm has a market capitalization of $298.21 billion, a price-to-earnings ratio of 16.57, a price-to-earnings-growth ratio of 2.44 and a beta of 0.26. The business has a 50 day simple moving average of $117.72 and a 200 day simple moving average of $103.08.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. The company had revenue of $16.40 billion during the quarter, compared to analyst estimates of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, equities research analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be issued a $0.85 dividend. The ex-dividend date is Monday, March 16th. This represents a $3.40 annualized dividend and a dividend yield of 2.8%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 46.70%.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: EU approval expands KEYTRUDA use to PD‑L1 positive, platinum‑resistant ovarian cancer — opens a new commercial indication in Europe for an established franchise, which can drive incremental revenue and utilization in a high‑unmet‑need setting. Merck Broadens Cancer And Eye Disease Pipeline As Investors Weigh Future Growth
• Positive Sentiment: Merck initiated a pivotal Phase 2b/3 trial of MK‑8748 (Tiespectus) for wet AMD — a promising ophthalmology program that, if successful, adds a non‑oncology growth vector and diversifies long‑term revenue streams. Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus)
• Positive Sentiment: Positive Phase 3 CORALreef results for oral PCSK9 inhibitor (enlicitide decanoate) — if approved, an oral PCSK9 could be a major commercial opportunity in cardiovascular prevention and complement existing lipid therapies. Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9
• Positive Sentiment: Detailed Phase 2 CADENCE data for WINREVAIR released — adds evidence to a respiratory program that management can highlight to investors as part of a broader R&D pipeline story. Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study
• Neutral Sentiment: Merck KGaA acquisition of JSR chromatography business noted in the press — this concerns Merck KGaA (a different company) and is unlikely to meaningfully affect Merck & Co.’s (MRK) near‑term fundamentals. Merck KGaA acquires JSR chromatography
• Negative Sentiment: New proposal from former President Trump to impose up to 100% tariffs on imported medicines (with carve‑outs) increases regulatory and pricing uncertainty for the sector; even with exemptions, the proposal raises near‑term headline risk and could pressure sentiment toward large pharma names like MRK until policy clarity emerges. Trump Unveils Up to 100% Tariffs on Imported Medicines With Key Exemptions
• Negative Sentiment: Sector policy debate over drug‑pricing deals continues (Lilly warns against locking pricing deals into law) — ongoing political scrutiny increases the chance of policy actions that could cap pricing or change reimbursement, a headwind for long‑term margin visibility. Lilly Pushes Back on Making Drug Price Deals Permanent

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, CEO Robert M. Davis sold 47,434 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $118.04, for a total transaction of $5,599,109.36. Following the completion of the transaction, the chief executive officer directly owned 443,602 shares of the company’s stock, valued at approximately $52,362,780.08. This trade represents a 9.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jennifer Zachary sold 121,573 shares of Merck & Co., Inc. stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total value of $14,485,422.95. Following the transaction, the executive vice president owned 68,916 shares in the company, valued at approximately $8,211,341.40. This trade represents a 63.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 320,176 shares of company stock valued at $38,281,735. 0.13% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. UBS Group upped their target price on Merck & Co., Inc. from $105.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Wolfe Research raised Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price target on the stock in a report on Thursday, January 8th. Morgan Stanley upped their price objective on Merck & Co., Inc. from $100.00 to $102.00 and gave the stock an “equal weight” rating in a research note on Friday, December 12th. Bank of America increased their target price on Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Finally, Deutsche Bank Aktiengesellschaft upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 target price on the stock in a research note on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $127.13.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.